Patients First
We’re Working Hard On Your Behalf
Our Commitment to Patient Well-Being
Neuvivo is honored to work with patient communities to discover new ways that improve and extend people’s lives. Our strong commitment to human health shapes the decisions we make and the actions we take daily. Our significant investment in research and development underpins our dedication to using science-based innovation to address some of the most challenging diseases like ALS. We understand the importance in providing information that patients and caregivers need in knowing what they can expect from Neuvivo. Only by working together can we improve outcomes for patients and change the practice of medicine.
EAP Status
We ask that you continue to visit our website (www.neuvivo.com) for updates or contact us at medinfo@neuvivo.com.
Our Mission
Our Story
A Second Chance for an ALS DrugPlease click here for a recent NPR interview (Feb 26, 2025) that Dr. Ari Azhir had with Dr. Moira Gunn on BioTech Nation.
Neuvivo was established on the voices and experiences of past trial participants and pledges to help those fighting terrible neurodegenerative diseases like ALS gain access to new treatments that may make a difference.— Ari Azhir, PhD, Founder and CEO.
Founders
Talented and Experienced Team
Our Board
Scientific Advisory Board
Cherished Advisors
ALS Is a ‘Neuro-Immunologic’ Disease
Neuroimmunology is the relationship between the body’s immune system and the nervous system. Given the heterogeneity of ALS pathogenesis, immunologic approaches to therapy have been difficult to advance.
Dysfunctional Innate Immunity in ALS
Current evidence in ALS implicates that the body’s own immune system plays a pivotal role in the destruction of motor neurons needed to control skeletal muscle control, including the diaphragm for breathing. Neuroinflammation thereby becomes a critical factor in disease progression and mortality.
One potential approach to treating ALS would be to supplement the “off switch” process by supplying a new source of taurine chloramine to help regain balance to this system.
Inflammation Destroys Neurons at the Neuromuscular Junction
A site where this breakdown occurs in ALS is at the neuromuscular junction where nerves and muscles connect. This results in the rapid decline of skeletal muscle function that may initially cause weakness but progresses to paralysis throughout the body. The diaphragm is the most critical skeletal muscle in our body needed for breathing. Vital capacity is an objective measurement used to track lung function in ALS patients and an important way of monitoring disease progression.
Key Takeaways:
- There is an unmet need for safe and effective ALS treatments to help the body regain balance over pro- and anti-inflammatory processes so that destruction is halted and healing potentially prevails across the neuromuscular system.
- Targeting inflammation at the neuromuscular junction may make a meaningful difference against ALS.
- Lung function as measured by vital capacity is an established predictor of quality of life, disease progression, and survival in ALS.
News
Press Releases
Careers
Join Our Team
The team at Neuvivo is committed to developing groundbreaking treatments for ALS and other motor neuron diseases.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, genetic information, national origin, protected veteran status, disability status, or any other characteristic protected by the law.
If you share our passion, we encourage you to contact us at careers@neuvivo.com
